Home - Products - Others - Other Targets - Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor

Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor

CAS No. 81483-91-2

Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor( ——— )

Catalog No. M42126 CAS No. 81483-91-2

Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor
  • Note
    Research use only, not for human use.
  • Brief Description
    Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor
  • Description
    Ac-[D-Lys2,Sar3]-Melanotropin-Potentiating Factor
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    81483-91-2
  • Formula Weight
    516.6
  • Molecular Formula
    C22H40N6O8
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • HM-30181 mesylate mo...

    HM-30181 mesylate monohydrate is an oral P-glycoprotein (P-gp) inhibitor, used to enhance the oral bioavailability of P-gp substrate drugs.

  • Licoarylcoumarin

    Licoarylcoumarin is a strong inhibitor of adenosine 3',5'-cyclic monophosphate (cAMP) phosphodiesterase. Licoarylcoumarin has antibacterial effects on the VRE strains; it has anti-HIV activity, and it has inhibitory effects on xanthine oxidase.

  • Porcine dynorphin A(...

    Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acute NMDA treatment.